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Dual GPCR and GAG mimicry by the M3
chemokine decoy receptor
Jennifer M. Alexander-Brett1,2 and Daved H. Fremont1,2,3
of Pathology and Immunology, 2Molecular Biophysics and Medical Scientist Training Program,
and 3Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110

Viruses have evolved a myriad of evasion strategies focused on undermining chemokinemediated immune surveillance, exemplified by the mouse ␥-herpesvirus 68 M3 decoy
receptor. Crystal structures of M3 in complex with C chemokine ligand 1/lymphotactin and
CC chemokine ligand 2/monocyte chemoattractant protein 1 reveal that invariant chemokine features associated with G protein–coupled receptor binding are primarily recognized
by the decoy C-terminal domain, whereas the N-terminal domain (NTD) reconfigures to
engage divergent basic residue clusters on the surface of chemokines. Favorable electrostatic forces dramatically enhance the association kinetics of chemokine binding by M3,
with a primary role ascribed to acidic NTD regions that effectively mimic glycosaminoglycan interactions. Thus, M3 employs two distinct mechanisms of chemical imitation to
potently sequester chemokines, thereby inhibiting chemokine receptor binding events as
well as the formation of chemotactic gradients necessary for directed leukocyte trafficking.
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fibroblast growth factor receptor; GAG, glycosaminoglycan;
GPCR, G protein–coupled
receptor; IP, IFN-inducible
protein; KD, dissociation constant; KI, inhibition dissociation
constant; MHV68, mouse herpesvirus 68; MIP, macrophage inflammatory protein;
NTD, N-terminal domain; pI,
isoelectric point; RMSD, root
mean square deviation; SPR,
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Chemokines orchestrate the migration of leukocytes under homeostatic and inflammatory conditions by signaling through G protein–coupled
receptors (GPCRs) expressed on trafficking immune cells. The chemokine family includes ⵑ50
members with 19 known receptors and is divided
into four subclasses based on the arrangement of
N-terminal cysteines (1, 2). Circulating leukocytes infiltrate tissues in response to cell-surface
chemokine gradients established through association with glycosaminoglycans (GAGs). These
ubiquitous sulfated polysaccharides influence
multiple cytokines (3) and specifically modulate chemokines by stabilizing gradients under
shear flow, protecting them from proteolysis,
and regulating their biological activity (4). GAG
binding also induces oligomerization of chemokines, which may be necessary for leukocyte recruitment in vivo (5, 6).
Large DNA viruses have evolved strategies
to avoid detection and clearance by the host (7),
including evasion of the chemokine network, an
important component of the immune response
to viral infection (8). Chemokines coordinate
innate and adaptive immunity by modulating
cellular recruitment, leukocyte activation, and
polarization of the immune response (9). Herpesviruses and poxviruses encode numerous proteins to subvert chemokine signaling, including
The online version of this article contains supplemental material.
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altered chemokine and GPCR variants, as well as
secreted decoy receptors that function as chemokine scavengers capable of inhibiting chemokine signaling and chemotaxis (10). Members
of the Orthopoxvirus and Leporipoxvirus genera
encode a conserved 35-kD decoy receptor, viral chemokine-binding protein, that selectively
binds CC chemokines and has been extensively
investigated biophysically (11–15). Recent work
has shown that some Orthopoxviruses encode additional chemokine inhibitors, termed smallpox
virus–encoded chemokine receptor domains (16),
which are encoded either alone or C-terminally
fused to secreted TNF decoy receptors and are
capable of sequestering select members of the
CC and CXC chemokine families. In contrast,
the expression of chemokine decoy receptors
by herpesviruses appears to be less generalized.
Examples include the glycoprotein G variants
encoded by ruminant α-herpesviruses that bind
CC and CXC chemokines (17), and UL21.5
from human cytomegalovirus that specifically
binds CC chemokine ligand (CCL) 5 (18). All
of the virally encoded chemokine decoy receptors identified to date are encoded by novel
sequences unrelated to any host proteins and
exhibit a variety of chemokine-binding profiles that may reflect differences in viral tropism
or pathogenesis.
Mouse -herpesvirus 68 (MHV68) is a natural
pathogen of rodents, closely related to Kaposi’s
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Table I.

M3 may be tailored to work cooperatively with other viral
proteins involved in pathogenesis.
We previously determined the crystal structure of M3
alone and in complex with the P8A variant of CCL2 (27),
which revealed significant details about how CC chemokine
sequestration is enabled by the decoy receptor. In this paper,
we describe the crystal structures of M3 in complex with
C chemokine ligand (XCL) 1, as well as wild-type CCL2.
These structures show that M3 engages two out of four chemokine classes with the same overall binding geometry and
stoichiometry. Comparative analysis reveals that the M3 Cterminal domain (CTD) engages conserved chemokine structural elements associated with GPCR binding, whereas the
acidic N-terminal domain (NTD) exhibits dramatic electrostatic complementarity with chemokines, contacting divergent basic clusters involved in GAG association. Based on
these observations, we have undertaken kinetic and mutational analyses to assess the role of electrostatics in M3 chemokine binding. We have also developed competition assays
to address whether M3 is capable of disrupting chemokine
interactions with GAGs. Collectively, our data reveal that the

Data collection and refinement summary for M3–chemokine complex structuresa

Data Set
Space group
Unit cell (Å)
Wavelength (Å)
x-ray sourceb
Resolution (Å) overall (outer shell)
Observations/unique
Completeness (%)
Rsym (%) (I >0)
I/
Refinement summaryc
Resolution (Å)
Reflections Rwork/Rfree (Fobs >0)
Molecules/ASU
No. protein residues/atoms/solvent
Rwork overall (outer shell) (%)
Rfree overall (outer shell) (%)
RMSD bond lengths (Å)/angles (°)
RMSD dihedral/improper (°)
Cross-validated Luzzati error (Å)
Ramachandran plot
Most favored/additional (%)
Generous/disallowed (%)
M3 domain B-values (Å2)

Chemokine B-values (Å2)

M3–CCL2

M3–XCL1

P3121
a = b = 99.23, c = 243.5
1
APS 19-ID
2.5 (2.61–2.5)
791,582/48,731
99.7 (100)
13.9 (41.2)
11.7 (4.1)

I212121
a = 85.44, b = 104.18, c = 290.85
1
APS 19-ID
2.6 (2.76–2.6)
674,773/40,275
99.3 (99.9)
10 (49.2)
16.1 (2.7)

20-2.5
45,669/2,258
6
1,299/10,113/546
23.2 (27.4)
29.9 (35.1)
0.006/1.4
25.3/0.87
0.47

20-2.6
33,788/1,771
4
865/6,720/192
22 (37)
27.3 (42.2)
0.007/1.4
25.2/0.98
0.46

86.8/12.9
0.3/0
A-NTD = 40.4/A-CTD = 31.7
B-NTD = 40.8/B-CTD = 31
X-NTD = 42/X-CTD = 31.2
D = 40.4, E = 39.9, Y = 40.2

83.2/16.4
0.4/0
A-NTD = 53.9/A-CTD = 55.6
B-NTD = 58.7/B-CTD = 44.5
D = 105.4, E = 78

aValues

as defined by SCALEPACK (reference 54).
bAdvanced Photon Source SBC-CAT beamline 19-ID.
cValues as defined in CNS (reference 57).
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sarcoma-associated herpesvirus and EBV, and serves as a model
system to study herpesvirus pathogenesis and latency (19).
The M3 protein encoded by MHV68 is the product of an
immediate-early transcript and is abundantly secreted during
acute infection (20). M3 disrupts chemokine signaling and
chemotaxis in vitro (21), and the phenotype of an M3-knockout virus is consistent with an immune evasion function
during central nervous system infection (22). M3 is the only
decoy receptor discovered thus far that binds members of all
four chemokine classes (21, 23); however, M3 displays selectivity within the CXC chemokine class, which may be functionally relevant for MHV68 pathogenesis. Mouse chemokines
shown to be up-regulated during MHV68 infection include
lymphotactin, monocyte chemoattractant protein 1, RANTES,
macrophage inflammatory protein (MIP) 1α, MIP-1, eotaxin,
IFN-inducible protein (IP) 10, MIP-2, and KC (24, 25). Of
these chemokines, only MIP-2 and KC are not bound by
M3 with high affinity. Strikingly, MHV68 also encodes a
chemokine GPCR, MHV68-encoded open reading frame
74, which signals in response to MIP-2 and KC but is antagonized by IP-10 (26). Thus, the chemokine-binding properties of

Published December 10, 2007
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M3 decoy receptor enables immune evasion through dual GAG
and GPCR mimicry, effectively preventing the establishment
of chemokine gradients and the activation of endogenous receptor signaling.

Similar M3 recognition features of XCL1 and CCL2
To determine the basis of promiscuous M3 engagement of
diverse chemokines, the M3–XCL1 and M3–CCL2 interfaces were analyzed to identify similar features of chemokine
recognition. Although XCL1 and CCL2 share only 24% sequence identity (70 aligned core residues), M3 binds to the
same general surface of each chemokine with a similar number of contacts. The shape complementarity of each interface is also comparable, averaging 0.66 for CCL2 and 0.63
for XCL1 (Table II). Comparison of our structures reveals
that M3 targets shared chemokine features that we have
parsed into three distinct regions, the chemokine N-terminal
segment, the hydrophobic seam, and the divergent basic

Table II. Structural analysis of M3–chemokine complexesa
complementarityb

Shape
BSAc (Å2)
Total
M3
Chemokine
M3 BSA (nonpolar/polar) (%)
Chemokine BSA (nonpolar/polar) (%)
Total contactsd (NTD/CTD)
H-bonds (NTD/CTD) (all same)

M3–CCL2

M3–XCL1

0.65, 0.66, 0.69

0.63, 0.62

2,084, 2,170, 2,134
1,071, 1,112, 1,087
1,013, 1,058, 1,049
66/34, 64/36, 66/34
58/42, 54/46, 59/41
132 (56/76),133 (51/82),126 (50/76)
12 (4/8)

2,156, 2,181
1,075, 1,090
1,081, 1,091
64/36, 68/32
57/43, 59/41
136 (67/69), 135 (65/70)
10 (4/6)

aTabulated

on a per-site basis in the order of chemokine chains D,E,Y and D,E, respectively, unless otherwise indicated.
using SC (reference 60).
cSolvent-accessible BSA calculated with 1.4 (Å) in NACCESS (reference 61).
dNonbonded contacts (<4 Å) calculated using HBPLUS (reference 62).
bCalculated
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RESULTS
Structures of M3 in complex with XCL1 and CCL2
To ascertain the structural features of M3 that facilitate promiscuous recognition of distinct chemokine classes, the structures
of M3 in complex with XCL1 and CCL2 were determined
and compared. XCL1 uniquely contains only a single disulfide,
herein referred to as the invariant disulfide, which is present
in all four chemokine classes. Otherwise, both chemokines
exhibit the characteristic chemokine-fold topology consisting
of an extended N-loop ending in a short 310-helix, followed
by three  strands connected by 30s and 40s loops and a
C-terminal α-helix (28, 29). Interestingly, the sequence of XCL1
is substantially longer than CCL2 (92 vs. 75 residues, respectively), although the last 20 residues beyond the C-terminal
helix have not been structurally defined.
The crystal structure of M3 in complex with XCL1 was
determined to a resolution of 2.6 Å (Fig. 1 A and Table I).
M3 is a two-domain protein that exists as a constitutive antiparallel homodimer, with two chemokine-binding clefts formed
between adjacent NTDs and CTDs at opposite ends of the
dimer. The M3–XCL1 model comprises a 2:2 complex, with
an asymmetrical M3 dimer caused by crystal contacts involving the A’-A–loop (residues 251–253) and the C”, D, and E
strands (residues 326–353) of the M3 A chain. XCL1 is deeply
buried within the binding cleft, which sequesters ⵑ1,080 Å2
of chemokine surface area (19% total). XCL1 contributes 15
residues and M3 17 residues to >130 contacts at the interface
(Table II), including 10 H-bonds, 3 of which form an antiparallel  strand between K8 and T10 of XCL1, and L273 and A275
of the M3 AB-loop. The two binding sites are strikingly similar, as reflected by the near equivalence of total buried surface
area (BSA) equaling 2,156 Å2 at the XCL1 (D) interface, and
2,181 Å2 for the XCL1 (E) interface, with no major differences in the number of contacts at each site (Table II).

We previously reported the structure of M3 in complex
with the P8A mutant of CCL2 (27). Substitution of Pro8 with
Ala has been clearly shown to disrupt CCL2 self-association
(30), and we were concerned that this mutant chemokine
might associate with M3 differently than wild-type CCL2.
To address this issue, we now describe the 2.5-Å resolution
structure of M3 in complex with wild-type CCL2. The model
consists of a 2:2 complex (Fig. 1 A), plus another half complex completed by crystallographic twofold symmetry, thus
providing two examples of the M3–CCL2 complex within
the same crystal. Overall, the M3 structures with wild-type
CCL2 and the P8A variant are almost identical, with a root
mean square deviation (RMSD) of 0.50 Å (all atoms) between
structures. Likewise, the two copies of the M3–CCL2 complex
are quite similar, differing by an RMSD of 0.48 Å (all atoms),
with comparable binding niches reflected by the total BSA in
each complex (4,254 vs. 4,268 Å2; Table II). We find that M3
contacts precisely the same surface of CCL2 as the P8A variant and utilizes equivalent residues to make the same number
of contacts (Table II). Neither the Pro8 nor Ala8 side chains
make any significant contact with M3, and indeed, the chemokine N-terminal strands adopt the same conformation as they
engage the M3 CTD. Importantly, all elements of GCPR
mimicry that we described previously are conserved in the
wild-type structure (27).
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Figure 1. Crystal structures of M3–XCL1 and M3–CCL2 complexes. Structures of (A) M3–XCL1 and (B) M3–CCL2. (left) Each complex displays a
2:2 stoichiometry, with M3 chains labeled A and B and chemokines labeled D and E. (middle) Space-fill models of XCL1 (E) and CCL2 (E). Sidechains of
contact residues are highlighted in magenta. Shared chemokine features are circled, with residues in the basic cluster (dashed line) labeled in blue; also
shown is the N-terminal segment (dotted line), with residues forming the antiparallel  strand labeled in black, as well as the hydrophobic cluster (bold
dotted line). Cysteines of the CC and C motifs are labeled on CCL2 (C11, C12, and C52; note that C36 is not visible) and XCL1 (C11 and C48), respectively.
The single disulfide in XCL1 is structurally equivalent to the second disulfide (C12–C52) in CCL2 and is referred to as the invariant disulfide. Conserved
sidechain contacts are italicized, and GAG-binding residues are indicated by asterisks (references 35, 38). (right) The chemokine contact surface is highlighted in magenta, with 2.5–3.5-Å (short-range) contacts in a darker shade and 3.5–5-Å contacts in a gradient from magenta to white. M3 sidechain
contacts are shown in stick form and labeled, with differential contacts highlighted with yellow labels and noncontacting residues shown in yellow for
each structure. (C) Structure-based sequence alignment of XCL1 (1–65) and CCL2 (1–70). All residues that contact M3 NTD or CTD are highlighted in cyan
3160
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Unique M3 recognition features of XCL1 and CCL2
Given the low degree of sequence identity between XCL1
and CCL2, the structures were also analyzed for unique features of chemokine engagement. An analogous total of 20
CCL2 and XCL1 residues are contacted by M3, with only 1
unique residue position contacted in each (K38 in CCL2 and
R43 in XCL1; Fig. 1 C). Remarkably, only five of these residues are conserved between the two chemokines, indicating
that the M3-engaged interfaces are no more sequence conserved than the overall proteins. To bind these extraordinarily
diverse interfaces, M3 uses 20 different residue sidechains,
of which 7 are differentially used (Fig. 1, A and B, right).
Many of the unique chemokine contacts are localized to the
N-loop, a region of high sequence variation among chemokines
because of its involvement in specific recognition by endogenous receptors (31). Although the extended N-loop adopts
similar conformations in CCL2 and XCL1, distinct binding

chemistries are used by M3 because of differences in primary
sequences. For example, although CCL2 R18 reaches out and
makes contact with the distally located M3 E129 and R170
sidechains, the structurally equivalent XCL1 residue Q17 instead hydrogen bonds with the more proximal M3 Q84. Near
the chemokine N-terminal segment, CCL2 Y13 and XCL1
V12 are both sequestered in a CTD hydrophobic pocket, but
the smaller XCL1 sidechain does not fill the pocket to the
same degree as Y13 and, consequently, does not make contact
with three M3 residues used by CCL2 (L273, P356, and T357;
Fig. 1, A and B, right). This difference in hydrophobic contact correlates with an overall decrease in the M3 CTD shape
complementarity value, which drops from 0.71 for CCL2 to
0.57 for XCL1. XCL1 also makes unique hydrophobic contacts
with M3 T226 via L45 that replaces CCL2 K49. Thus, M3 is
able to accommodate variable chemokine sequences through
uniquely arrayed contact chemistries.
M3 structural plasticity
To further ascertain how M3 is able to similarly engage two
diverse chemokines, the conformational variation exhibited
by the decoy receptor was assessed. We previously hypothesized that promiscuous ligand binding might be facilitated
by the structural plasticity of the M3 chemokine-binding
niches (27). Indeed, structural comparison of unliganded M3
with the M3–CCL2 (P8A) complex revealed significant conformational rearrangements associated with ligand binding,
including loop remodeling and domain movements of up
to 8°. Comparison between the M3–CCL2 and M3–XCL1
complexes indicates a more modest degree of plasticity, with
an overall RMSD of 0.7 Å for all M3 atoms with only minor domain movements. The conformational variation that
is exhibited can best be understood in the context of how
the M3 NTD and CTD differentially interface each chemokine. Although the chemistry and geometry of the chemokine
N-terminal segments engaged by the M3 CTD are highly
similar, significant sequence and conformational variation in
the basic N-loop, 310-helix, and 40s loop regions flanked
by the acidic M3 NTD is readily apparent (Fig. 1 D). The M3
NTD adapts to these localized chemokine differences through
sidechain and loop repositioning, along with an ⵑ2° rigid
body rotation, which collectively result in a maximal Cα displacement of ⵑ2.5 Å at the top of the s2b-s3 loop. Thus, with
XCL1 bound, the rearranged NTD is optimally positioned
for M3 E80 and E81 to engage R23 and R43 of the XCL1 basic cluster. Additionally, the repositioned NTD effectively
narrows the binding niche, thereby maintaining close contact with parts of the hydrophobic seam, which is organized
in XCL1 to include L19, P20, and L45. Hence, although the

and blue, respectively, with disulfide-forming cysteines in black. Conserved sidechain contacts are indicated by gray triangles and GAG-binding residues
with asterisks. (D) Conformational rearrangement of M3 NTD with the Cα trace of M3–CCL2 in gray and M3–XCL1 superimposed in blue, cyan, and magenta. (E) RMSD (all atoms) between M3 in complex with XCL1 and CCL2 is highlighted on the trace of M3–XCL1 as a gradient from white to red (from
0.5 to ≥3 Å). Figures were prepared using Ribbons (reference 67) and GRASP (reference 68) software, as previously described, and the chemokine E chain
interface is shown as the reference in all figures.
JEM VOL. 204, December 24, 2007
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cluster (Fig. 1, A and B, middle). M3 engages both chemokines by contacting their common N-terminal segment, which
includes the invariant disulfide bond and adjacent residues.
The M3 CTD makes several conserved contacts within this
segment, including the packing of M3 P272 against the invariant
disulfide, burial of hydrophobic chemokine residues (CCL2 Y13
and XCL1 V12) within a pocket formed by the M3 AB- and
EF-loops, and formation of an antiparallel  strand between
the M3 AB-loop and the N-terminal chemokine backbone.
Central to each interface is a stretch of hydrophobic chemokine residues recognized by both M3 domains, termed the
hydrophobic seam, situated in the N-loop region underneath
the 40s loop. The two chemokines share major hydrophobic
contacts in this region, specifically CCL2 residues I20 and I42,
which are structurally analogous to XCL1 residues L19 and
I38. Adjacent to the chemokine hydrophobic seam is a cluster of divergent basic residues in the N-loop, 310-helix, 40s
loop, and C-terminal helix, which are engaged by the acidic
M3 NTD. Electrostatic complementarity between acidic loops
of the NTD and the basic cluster of each chemokine is a
prominent feature of the shared interface. Specifically, 15 Glu
and Asp residues of the s2b-s3, s4-s5, and s7-s8 loops of the
M3 NTD are located opposite 9 (XCL1) and 6 (CCL2) Arg
and Lys chemokine residues. Interestingly, although the basic
cluster is a common feature of both chemokines, residues
composing the cluster are variably positioned, and consequently, the only conserved interaction within this region
is between XCL1 R23 and CCL2 R24 and the backbone
carbonyl of M3 E81. Thus, M3 recognizes several conserved
elements of chemokine structure that are shared between these
CC and C family chemokines.
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M3 CTD maintains a rigid interface to contact chemokine
N-terminal structural elements conserved between XCL1
and CCL2, the NTD capably tracks the unique display of
chemokine basic and hydrophobic residues through concerted
reconfiguration.

M3–chemokine association is enhanced by electrostatics
To address the contribution of electrostatics to the interaction
of M3 with chemokines, binding kinetics were examined by
surface plasmon resonance (SPR) to determine apparent on
and off rates. SPR analysis of chemokines binding to immobilized M3 revealed a common feature of relatively fast apparent on rates (≥107 M1s1) at 150 mM NaCl. To further
investigate this phenomenon, XCL1 binding was assessed
as a function of increasing ionic strength, which effectively
screens electrostatic interactions that can enhance protein association rates (Fig. 2 B and Table III) (32). This series of measurements revealed that the M3–XCL1 apparent on rate (kaapp)
is greatly reduced at high NaCl concentrations, decreasing

M3 NTD acidic loops mediate electrostatic on-rate
enhancement
Given that electrostatic complementarity is concentrated at
the M3 NTD interface, the role of acidic NTD loops in enhancement of M3–chemokine apparent on rates was examined. A structure-based M3 variant, termed M3BBXB, was created
by mutating the sequence 80EELGQ84 to 80SRRGR84 (Fig. 3 A).
The mutant was designed with the goal of reducing electrostatic complementarity at the NTD interface by introducing

Table III. NaCl dependence of M3–XCL1 binding kinetics
NaCl (M)
0.2
0.25
0.3
0.35
0.4
0.5
0.6
0.7
1
1.25
1.5
aAverage

3162

KD(eq) (Req) (nM)

KD(kd/ka) (nM)

kaapp (M1s1) ×107

kd app (s1) ×102

2 avga


2.6 (±0.4)
4.6 (±0.5)
6.9 (±0.8)
9 (±0.9)
11 (±1)
16.2 (±0.8)
18.8 (±0.9)
21 (±2)
28 (±2)
26 (±6)

0.9 (±0.2)
1.8 (±0.4)
3 (±0.5)
4.6 (±0.6)
7 (±1)
9 (±1)
12 (±1)
17 (±2)
17 (±2)
19 (±0.8)
22 (±2)

6 (±1)
5 (±2)
3 (±1)
2.2 (±0.7)
1.6 (±0.4)
0.9 (±0.2)
0.33 (±0.04)
0.24 (±0.02)
0.19 (±0.03)
0.13 (±0.01)
0.083 (±0.003)

5.6 (±0.2)
9 (±3)
9 (±2)
10 (±2)
10 (±2)
9 (±1)
3.9 (±0.6)
4.2 (±0.5)
3.1 (±0.3)
2.5 (±2)
1.9 (±0.1)

21.61
2.15
0.49
0.35
0.4
0.3
0.49
0.69
0.56
0.37
0.52

2 for global kinetic fits at three ligand densities measured in triplicate.
DUAL GPCR AND GAG MIMICRY BY M3 | Alexander-Brett and Fremont
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Electrostatic complementarity between M3 and chemokines
These structures reveal that for both CCL2 and XCL1, the
flexible M3 structure adapts to optimize contacts with the
basic cluster on an individual basis. This suggests that electrostatics may be an important element of promiscuous chemokine
sequestration by the M3 NTD. To further assess the complementarity between M3 and chemokines, electrostatic potential maps were calculated for M3, XCL1, and the M3–XCL1
complex revealing that the positive potential of the XCL1
basic cluster is located directly opposite the negative potential
of the M3 NTD acidic loops, and that both are significantly
neutralized in the complex (Fig. 2 A). To demonstrate this
charge neutralization biochemically, the M3 isoelectric point
(pI) was experimentally determined (ⵑ4.5) and was found to
increase by >1 pH unit in complex with either chemokine
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071677/DC1). Collectively, these data lend support for
the hypothesis that electrostatics are important components
of M3–chemokine interactions.

by almost two orders of magnitude (70-fold) from 7 × 107 to
8 × 105 M1s1 (Fig. 2 C). This trend is also reflected in the dissociation constant (KD), which increases from 0.9 to 22 nM
between 200 mM and 1.5 M NaCl. In contrast, the M3–XCL1
apparent off rate (kdapp) was relatively unperturbed over the
range tested, varying only fivefold. A computational analysis
of the M3–XCL1 structural interaction predicts a congruent
trend in the calculated electrostatic interaction energy as a
function of ionic strength, indicating that electrostatics contribute favorably to the free energy of interaction and, thus,
enhance the binding affinity (Fig. S1 and Table I). It was also
of interest to determine the on rate at lower salt concentrations; however, severe mass transport effects precluded analysis below 200 mM NaCl. Therefore, the experimental trend
was extrapolated to obtain rough estimates for kaapp at low salt
(Fig. S1 and Supplemental materials and methods, available at
http://www.jem.org/cgi/content/full/jem.20071677/DC1).
For example, extrapolation to zero salt leads to an estimated
on rate of ⵑ4 × 1011 M1s1, suggesting that electrostatic
forces would draw M3 and chemokines together at a rate much
faster than diffusion alone (ⵑ109 M1s1) (33). Importantly,
the extrapolated on rate at physiological NaCl (150 mM) is
ⵑ108 M1s1, which is two to three orders of magnitude
faster than typical protein–protein interactions. Collectively,
these kinetic and computational analyses clearly indicate that
electrostatics facilitate fast M3–chemokine complex formation, and further, suggest that M3–XCL1 association may be
among the most rapid protein–protein associations yet described (32, 34).
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Figure 2. Kinetic analysis of M3–XCL1 interactions. (A) Corey-Pauling-Koltun model of M3, XCL1, and the M3–XCL1 complex with an overlay of
electrostatic potential maps from APBS (150 mM NaCl) in mesh, contoured at 0.7 kT/e and displayed using Chimera, as previously described (reference
69). Surface area buried in the complex is highlighted in green (XCL1) and yellow (M3), and both are labeled with experimental pI’s. (B) Representative SPR
sensorgrams (gray) and fits (red) for XCL1 binding to M3 as a function of NaCl. (C) Binding constants for the NaCl range investigated (from 200 mM to
1.5 M; Table III). (top) The on rate (kaapp) and off rate (kdapp) as a function of NaCl (mean ± SEM). (bottom) KD (from the ratio of on and off rates) and KD(eq)
(from nonlinear fit to Req values; mean ± SEM).
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Arg residues in the M3 s2b-s3 loop opposite basic chemokine
sidechains in the N-loop and 40s loop. As anticipated, the
M3BBXB mutant is less acidic than wild-type M3, with a pI
shifted to ⵑ5, almost to the same degree as seen for wild-type
M3 in complex with chemokine (Fig. S1). To assess whether
this reduction of M3 surface charge results in a slower on rate
for chemokine binding, kinetic analysis was performed for
XCL1 binding to M3BBXB at 150 mM NaCl (Fig. 3 B). Indeed,
the mutant displays a significantly reduced on rate, which is
1.8 × 106 M1s1, a decrease of ⵑ100-fold compared with
wild-type estimates (Table IV). In contrast, the off rate for
M3BBXB is relatively unchanged at 0.043 s1 compared with
ⵑ0.06 s1 for wild-type (200 mM NaCl), corresponding to a
half-life of ⵑ15 s for both. Together with the salt-dependent
kinetic analysis, these results suggest that electrostatics facilitate on-rate enhancement but do not contribute as much to
complex half-life for this chemokine. Furthermore, analysis
of the M3BBXB mutant firmly establishes an important role
for the acidic NTD loops in the electrostatic enhancement of
M3–chemokine on rates.
Assessment of M3 chemokine binding by SPR competition
We exploited the reduced on rate of the M3BBXB variant to
develop an SPR assay that facilitates the measurement of
wild-type M3 binding to chemokines in solution, thereby
avoiding the mass transport surface effects that limited analysis at 150 mM NaCl. To this end, M3BBXB was immobilized
on the sensor chip, and the solution affinity for XCL1 binding
to wild-type M3 (inhibition dissociation constant [KI]) was
obtained by titrating coinjected M3 that competes for XCL1
binding to immobilized M3BBXB (Fig. 3 C; a complete description of the assays is provided in Supplemental materials and
methods). This competition assay yielded a solution affinity
for XCL1 binding to M3 of KI = 500 (±70) pM (Table IV).
By comparison, extrapolation of our salt-dependent data estimates an apparent on rate of ⵑ108 M1s1 and an off rate of
ⵑ0.06 s1, yielding a KD from the kinetic ratio of ⵑ600 pM.
Thus, the M3–XCL1 affinity determined by competition at
150 mM NaCl is remarkably consistent with that extrapolated
from our limited kinetic analysis.
M3 stoichiometrically inhibits chemokine–GAG interactions
The experiments described thus far have established that
electrostatic interactions with the M3 NTD profoundly enhance chemokine on rates. Electrostatics are also an important component of chemokine–GAG interactions, exemplified
by their salt dependence (35), the importance of N- and Osulfation of GAGs (36), and the role of residues in the chemokine basic cluster (4). In support of this concept, previous
studies have shown that the addition of M3 to heparin-binding assays reduces GAG binding for some chemokines (37).
To address whether M3 could directly inhibit GAG interactions for diverse chemokines, an SPR competition assay
was developed (Fig. 4). Initially, chemokine-binding affinity
for immobilized heparin was measured, and chemokine was
titrated with coinjected M3 to assay inhibition of heparin
3164

Figure 3. M3BBXB kinetics and M3 competition assay. (A) Positions mutated in M3BBXB and adjacent basic residues on XCL1 are
shown in ball and stick form (oriented as in Fig. 1 A), and mutations
are listed. Adjacent sections of the chemokine backbone are not shown,
for clarity. (B) XCL1 binding to M3BBXB. Representative sensorgrams
(gray) and Req values (plot, inset) are shown with corresponding fits
(red and black, respectively; Table IV). (C) Competition assay to determine the solution affinity for M3 binding to XCL1 at 150 mM NaCl.
Competition titration curve for coinjected M3 binding to XCL1 in competition with immobilized M3BBXB is shown with a corresponding fit to
the data (Table IV).
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Table IV.

M3 binding affinity and kinetics at 150 mM NaCl

M3 variant–chemokine
M3–XCL1a
M3BBXB–XCL1

KD(eq) (Req) (nM)

KD (kd/ka) (nM)

ka (M1s1) ×107

kd (s1)

0.5 (±0.07)
59 (±6)

ⵑ0.6
23 (±1)

ⵑ10
0.18 (±0.01)

ⵑ0.06
0.043 (±0.004)

aEstimates (~) for on and off rate derived from extrapolation of salt-dependent kinetics, kinetic-based K was determined from the ratio of these estimates, and equilibriumD
based KD(eq) was determined by competition assay (referred to as KI in the text).

Table V.

Heparin-binding and M3 competition assay
Heparin

M3 competition

Chemokine

KD (Req) (nM)

KI (nM)

CCL2
XCL1
CXCL10

1,200 (±200)
90 (±10)
60 (±10)

18 (±7)
2.3 (±0.7)
0.9 (±0.3)

JEM VOL. 204, December 24, 2007

manner (unpublished data). As expected, the other control
GAG-binding proteins, VEGF (Fig. 4 C) and FGFR (not
depicted), were completely unaffected by incubation with M3,
confirming that GAG blockade by M3 is chemokine specific.
Collectively, these complementary GAG competition assays
demonstrate that M3 specifically blocks chemokine–GAG
interactions in a stoichiometric manner, disrupting cell adhesion for chemokines that display widely different GAG affinities
and binding modes.
DISCUSSION
GPCR mimicry by the M3 CTD
The M3–XCL1 and M3–CCL2 structures reveal that GPCR
mimicry by the M3 CTD is conserved for at least two chemokine subclasses. The most evident element of structural
mimicry is the hydrophobic packing of M3 P272 against the
chemokine invariant disulfide (Fig. 1), which mimics the
interaction observed for an N-terminal peptide of CXC
chemokine receptor 1 in complex with CXCL8 (27, 41).
M3 P272 packs against the invariant disulfide in precisely the
same manner as P29 of CXC chemokine receptor 1, and given
that proline is highly conserved at this position among chemokine receptors, this may represent a general mode in which
the invariant disulfide is recognized by GPCRs. Interestingly,
CXCL8 N-loop interactions with the CXCL1 peptide do
not appear to preclude chemokine dimerization through the
1 strand. If the M3–chemokine binding mode is conserved
for all classes, it is possible that CXCL8 could also bind to M3
as a dimer, and in fact, preliminary data for the M3–CXCL8
complex are consistent with this hypothesis. In addition,
hydrophobic residues immediately after the invariant disulfide bond, CCL2 Y13 and XCL1 V12, are both sequestered
within the CTD hydrophobic pocket. Virtually all high affinity M3 ligands harbor a Tyr, Phe, or aliphatic sidechain at
this position, which also appears to be important for receptor
recognition (42, 43). This suggests that the CTD sequesters
another key position engaged by GPCRs in general. Likewise, the M3 AB-loop forms an antiparallel  strand with
residues in the N-terminal segment that participate in receptor binding and signaling (39). Interestingly, the H-bonds
within this strand are identically positioned for XCL1 and
CCL2, unperturbed by differences in the disulfide bonding
patterns of each chemokine. This suggests that the M3 ABloop recognizes an N-terminal backbone conformation that
is common to chemokines of different subclasses within a
region important for GPCR recognition. In summary, the
two complex structures presented in this study demonstrate
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binding (Fig. 4). This analysis was ultimately performed for
members of three out of the four classes of chemokines, as
CX3CL1 exhibited very low affinity for heparin (unpublished data). Analysis of CCL2, XCL1, and CXC chemokine
ligand (CXCL) 10 binding to heparin yielded KD estimates
(Fig. 4 A and Table V) in agreement with previous papers
(35, 38), as XCL1 and CXCL10 exhibited nanomolar affinity
and CCL2 micromolar. Qualitative assessment of sensorgrams
shows that XCL1 and CXCL10 display relatively slow multiphasic association kinetics and long-lived complexes in comparison with the rapid kinetics observed for CCL2, reflecting
the diverse nature of these individual chemokine–GAG interactions. Results of the M3 competition assay show that M3
blocks CC, C, and CXC chemokine binding to GAGs in
a stoichiometric manner, as M3 completely inhibits heparin binding for all chemokines at nearly a 1:1 molar ratio
(Fig. 4 B). Furthermore, estimates for the M3 dissociation
constant (KI) in competition with heparin are in the picomolar–nanomolar range (Table V), suggesting that M3 could
effectively inhibit GAG-binding at physiologically relevant
chemokine concentrations (39).
A cellular competition assay was also conducted to assess
M3 inhibition under conditions that more closely reflect the
GAG environment in vivo. Chinese hamster ovary (CHO)–
K1 cells, rich in heparan sulfate and chondroitin sulfate, were
stained with CCL2, XCL1, and CXCL10, as well as the control GAG-binding proteins vascular endothelial growth factor (VEGF) and soluble fibroblast growth factor receptor
(FGFR; unpublished data), in the absence and presence of
equal molar amounts of M3. The GAG-deficient CHO-745
line (40) was also stained as a control. The results clearly show
that all chemokines and control proteins bind to GAGs on
CHO-K1 cells. In the presence of M3, staining is specifically
reduced for all three chemokines, with CCL2 and CXCL10
staining completely reduced to the level of the 745 cells.
The incomplete inhibition observed for XCL1 appears to
be an artifact of nonspecific biotinylation, as similar results
were obtained for other chemokines labeled in the same
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Figure 4. Heparin-binding and M3 competition assays. (A, left) Representative SPR traces for chemokines binding to immobilized heparin. Note that
chemokines display multiphasic-binding kinetics, which therefore precluded kinetic analysis using a simple bimolecular interaction model. (right) Req values for chemokine binding to heparin with corresponding nonlinear fits to obtain KD for each interaction (Table V). Equilibrium (Req) binding for CCL2 and
CXCL10 was described well by a simple 1:1 interaction model; however, XCL1 displayed cooperative binding behavior and, thus, a more complex model
was used (Supplemental materials and methods). (B) Competition titration curves with corresponding fits for coinjected M3 inhibition of XCL1, CCL2, and
CXCL10 binding to immobilized heparin (Table V). (C) FACS analysis of chemokine binding to CHO-K1 (wild-type) and CHO-745 (GAG-deficient) cell lines.
Staining of CHO-745 cells is shown in violet for XCL1, CCL2, CXCL10, and VEGF control, with staining in the absence (green) and presence (magenta) of
M3 superimposed.

that M3 engages several conserved chemokine structural features associated with GPCR binding, including the invariant
disulfide, adjacent hydrophobic residues, and the common
N-terminal segment.
3166

Prominent role of electrostatics in M3–chemokine
interactions
This study has also demonstrated that electrostatic interactions
are a conserved element of chemokine recognition by the
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GAG mimicry by the M3 NTD
The SPR competition and CHO cell-surface assays reported
in this paper demonstrate that M3 blocks GAG interactions
for the chemokines CCL2, XCL1, and CXCL10. We have
shown that electrostatic interactions between the divergent
basic cluster found on chemokines and the acidic M3 NTD
facilitate this blockade. GAGs are flexible linear polysaccharides heterogeneously decorated with acidic sulfate and carboxylate groups that engage chemokine basic clusters in a
highly diverse manner (4). A comparison of available mutational data for CCL2 (35, 44) and XCL1 (38) with our complex structures reveals that the majority of residues implicated
in GAG binding are also engaged by M3 (Fig. 5, A and B).
Specifically, the M3 NTD directly contacts four out of six
residues identified by mutational analysis of CCL2, and two
out of four residues of XCL1, with a prominent role played
by E80 and E81 in the M3 s2b-s3 loop. The contacted chemokine residues are located in the N-loop, 310-helix, and 40s
loop, whereas the noncontacted residues are located in the
1 strand and C-terminal helix. Importantly, we note that
our SPR and cell-surface binding assays demonstrate the disJEM VOL. 204, December 24, 2007

ruption of CCL2 and XCL1 interactions with GAGs despite
the fact that M3 does not make contact with all of the surface
epitopes identified for these chemokines.
Because most chemokines harbor a basic cluster located
in roughly the same position as CCL2 and XCL1, the coincidence of GAG-binding residues with M3 NTD contacts
may in fact be a more general phenomenon. In this study,
we have shown that M3 capably disrupts the interaction of
CXCL10 with GAGs, and that three out of four residues implicated in GAG binding (45) are located in the 310-helix and
40s loop, forming a basic cluster that maps to approximately
the same location as where CCL2 and XCL1 basic residues are
contacted by the M3 NTD (Fig. 5 C). Computational docking studies indicate that M3 could readily contact CXCL10
R22, K46, and K47 but would unlikely contact K26 located
on the 1 strand. Nevertheless, as for CCL2 and XCL1, we
suggest that partial engagement of the basic cluster is sufficient
for complete blockade. Functional and structural mapping of
GAG binding to another MHV68 up-regulated chemokine,
CCL5, provides further support for the notion of M3 GAGbinding mimicry (Fig. 5 D). The M3-contacted residues K49
of CCL2 and R43 of XCL1 are located in the same 40s loop
region as the BBXB motif residues of CCL5 (46). Furthermore, the crystal structure of a CCL5–heparin disaccharide
complex reveals that the 40s loop BBXB residues directly
contact sulfate and carboxylate moieties of the carbohydrate
(47). Analogously, the 40s loop basic residues of XCL1 and
CCL2 interact with carbonyl and carboxylate moieties from
the M3 s2b-s3 loop. Thus, M3 acts as a functional GAG
mimic for chemokines, using similar chemical means (absent
sulfation) to competitively disrupt chemotactic gradient formation, thereby preventing inflammation at sites of MHV68
infection (Fig. 5 E).
Collaborative nature of the two-domain M3
binding interface
In this paper, we have demonstrated that M3 can stoichiometrically block GAG interactions for three chemokines with
similar albeit not identically located basic clusters that apparently facilitate distinct modes of heparin binding, as revealed
by our SPR analysis. The M3–XCL1 and M3–CCL2 structures reveal how M3 is able to block such diverse interactions
by interfacial reconfiguration that optimally engages the unique
GAG-binding residues of each chemokine. Notably, M3 is
not effective against other GAG-binding proteins, including
VEGF and soluble FGFR. This is most likely a result of dual
chemokine recognition by the two-domain M3 interface
(Fig. 5 F), which effectively ensures that GAG blockade is
chemokine specific.
M3 is the only decoy receptor known to recognize chemokines with a two-domain interface and, accordingly, displays
the broadest chemokine-binding profile, engaging members
of all four classes with high affinity (10). Thus, an important
advantage of two-domain recognition may be promiscuous
binding. We argue in this paper that GPCR and GAG mimicry can be primarily attributed to functions of the M3 CTD
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M3 NTD and play an important role in chemokine sequestration by this decoy receptor. The structures presented in
this study reveal that electrostatic complementarity is a prominent feature of the M3 binding interface, with the acidic
M3 NTD adapting to engage the divergent chemokine basic
cluster in each case. The importance of electrostatics in
M3–chemokine interactions is highlighted by our kinetic and
mutational analyses showing that M3 rapidly associates with
chemokines, with an on rate that is remarkably enhanced by
electrostatic interactions with the acidic M3 NTD. Electrostatic complementarity may in fact be a common mechanistic
strategy among pathogen-encoded chemokine decoy receptors. For example, the poxvirus viral chemokine-binding
proteins have pI’s nearly as acidic as M3, and chemokine basic cluster residues play an important role in binding (14, 15).
Similarly, when M3 is compared with some of the fastest
electrostatically enhanced interactions found in biology, it is
evident that all of these systems share the common goal of
rapid inhibition. Other proteins have evolved fast association
kinetics to necessarily achieve instant blockade of harmful
enzymatic processes or neutralization of toxic intermediates
(32, 34). In the case of M3, rapid chemokine sequestration
may be necessary to prevent the establishment and spread of
gradients early during infection. M3 is abundantly secreted
by virally infected cells but is still overshadowed by the high
level of GAG expression in the extracellular matrix. The
concentrated negative potential of the M3 NTD may therefore be required to serve as an electrostatic beacon, attracting
chemokines over long range, increasing their rate of association, and allowing M3 to compete with GAGs that are in vast
excess. Thus, by rapidly sequestering chemokines before gradients are established, M3 could mitigate the ensuing consequences of chemokine signaling that are essentially toxic to
the virus.
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Figure 5. Dual GPCR and GAG inhibition by M3. (A) Surface representation of CCL2 is shown, with previously identified GAG-binding residues labeled (references 35, 44). Four out of the six residues defined by mutational analysis as creating the GAG-binding epitope of CCL2 are directly contacted
by M3 and are colored blue (Arg18, Lys19, Arg24, and Lys49), whereas the noncontacted residues are colored gray (Lys58 and His66). The M3 NTD s2b-s3 loop
is displayed in cyan, with acidic contact residues E80 and E81 shown in stick form. (B) M3 contacts two out of the four previously identified GAG-binding
residues of XCL1 (R23 and R43, blue; K25 and R70, gray; reference 38). (C) The structure of human CXCL10 (reference 70) is shown, with the four conserved GAG-binding residues identified by mutational analysis in mouse IP-10 highlighted in blue (R22, K26, K46, and K47; reference 45). (D) The structure
of CCL5 is shown, with GAG-binding residues established by structural and mutational analysis highlighted in blue (R44, K45, and R47; references 46, 47).
(E) Proposed model for the disruption of chemokine gradients by M3 during MHV68 infection. (F) Schematic of M3 NTD-mediated disruption of chemokine interactions with cell-surface GAGs (green) and CTD-mediated disruption of chemokine interactions with GPCRs (violet). The electrostatic potential
is indicated by red (+) and blue () on chemokines and GAGs, respectively.
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MATERIALS AND METHODS
DNA constructs, protein expression, and purification. Full-length,
untagged M3 protein was expressed in baculovirus-infected insect cells (SF9)
and purified as previously described (27). The M3BBXB (80EELGQ/SRRGR84)
variant was created by quick-change site-directed mutagenesis (courtesy of
V. van Berkel, Washington University, St. Louis, MO), expressed using
baculovirus, and elutes from size-exclusion chromatography with the same
(dimeric) profile as wild-type M3. Full-length synthetic human XCL1 (residues
1–92) and Escherichia coli–produced human CCL2 (M64I) used in crystallization (courtesy of T. Handel, University of California, San Diego, La Jolla,
CA) were made as previously described (30, 53). For cell staining, CCL2
JEM VOL. 204, December 24, 2007

(M64I) and CXCL10 were cloned into a customized pET28 vector with a
thrombin-cleavable C-terminal tag designed for site-specific biotinylation
(courtesy of M. Miley, Washington University, St. Louis, MO). Proteins were
expressed in E. coli as inclusion bodies, were refolded under oxidizing conditions, and were purified by ion exchange. The C-terminal tag was removed
from CCL2 and CXCL10 before SPR analysis.
x-ray crystallography. M3–CCL2 crystallized in the space group P3121
(a = b = 99.23, c = 243.5), and M3–XCL1 crystallized in the space group
I212121 (a = 85.44, b = 104.18, c = 290.85). Crystallographic data were collected in the beamline 19-ID at the Advanced Photon Source. Diffraction
intensities were integrated and scaled using the HKL2000 program suite, as
previously described (54). The phase problem was solved by molecular replacement in AMoRe, as previously described (55), using M3–CCL2 (P8A)
(available from the Protein Data Bank under accession no. 1ML0) as a search
model. For M3–XCL1, prime-and-switch phasing was used to reduce modelphase bias in the initial maps with RESOLVE, as previously described (56).
Model building was undertaken with O, as previously described (57), and
refinement against 2.6-Å resolution data was performed using the Crystallography and Nuclear Magnetic Resonance System (CNS), as previously
described (58), with a final R-value of 22% and a free R-value of 27.3% (5%
test set). The atomic model consists of a 2:2 complex related by noncrystallographic symmetry (NCS), including residues 12–382 of M3 (chains A and B)
and residues 7–67 and 7–72 of XCL1 (chains D and E, respectively). The
first 11 residues of M3 were not located, nor were the first 6 and last 26 for
XCL1 D, and the first 6 and last 21 for XCL1 E. For the M3–CCL2 complex, refinement was performed to a resolution of 2.3 Å, with a final R-value
of 23.2% and a free R-value of 29.9% (5% test set). The atomic model consists of three M3 molecules (residues 12–382) and three CCL2 molecules
(residues 8–71), representing one 2:2 complex (NCS) and a half complex
completed by the crystallographic twofold symmetry axis (CS).
Structure analysis. Structure analysis was performed for the 2:2 M3–XCL1
complex and for the NCS and CS complexes of M3–CCL2. LSQKAB (59)
was used to calculate RMSD between M3 Cα atoms of AB (NCS) and
X (CS) of M3–CCL2 and M3–CCL2 (P8A). RMSD between M3 (all atoms)
in complex with XCL1 and CCL2 was calculated using CNS, as previously
described (58). For RMSD on a per-residue basis, values were calculated for
the two (XCL1) and three (CCL2) interfaces and subsequently averaged.
SC, as previously described (60), was used to calculate the shape complementarity for each binding interface. NACCESS, as previously described (61),
was used to analyze the BSA. HBPLUS, as previously described (62), was
used to enumerate atomic contacts (≤4 Å) and H-bonds.
Electrostatic analysis. The ln(ka) was plotted versus 1/1 + a over the
range of salt concentrations studied to yield an estimate for the M3–XCL1
kaapp at 150 mM NaCl of ⵑ108 M1s1 (Supplemental materials and methods).
In addition, to test the role of protein–ion binding in M3–XCL1 interactions,
measurements were conducted under the same ionic strength using either
NaCl or MgCl2 (Fig. S1 and Table S1, available at http://www.jem.org/
cgi/content/full/jem.20071677/DC1). The program APBS was used to calculate potential maps and electrostatic interaction energies (Gelec) for the
M3–XCL1 interaction (Supplemental materials and methods).
SPR experiments. SPR experiments were conducted using a biosensor
(Biacore 2000; GE Healthcare). All experiments were conducted at 25°C
under conditions of 20 mM Hepes (pH 7.4), 150 mM NaCl, and 0.005%
Triton X-100, unless otherwise indicated. A detailed description of all SPR
experiments is provided in Supplemental materials and methods.
For M3–chemokine interaction analysis, M3 variants were immobilized
on a Biacore CM5 sensor chip in 10 mM sodium acetate, pH 4.1, using standard
amine coupling. To measure M3–XCL1 binding kinetics as a function of NaCl,
M3 was immobilized on the sensor chip and 80 l/min XCL1 was injected.
Data were collected over the range from 200 mM to 1.5 M NaCl. To measure M3BBXB binding to XCL1, the mutant was immobilized and 40 l/min
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and NTD, respectively (Fig. 5 F). This parsing of roles allows
M3 to recognize conserved chemokine structural elements
through the CTD and, at the same time, imparts structural
plasticity to the interface for adaptation of the NTD to divergent chemokine features. With collaboration between the
two domains of the interface, it is possible for each to make a
unique contribution to the overall affinity of M3–chemokine
interactions. Our mutational analysis supports the notion that
the NTD contributes long-range electrostatic interactions
to rapidly steer chemokines into the binding niche, where
short-range hydrophobic and H-bond interactions subsequently
form with the CTD, ultimately resulting in a long-lived complex. Indeed, the M3BBXB variant exhibits a dramatically attenuated ability to recruit XCL1 compared with wild-type
M3 (100-fold on-rate reduction) but is capable of stable
sequestration with equivalent complex half-lives. It will be
of great interest in the future to assess whether short-range
interactions contributed by the CTD play a role in determining the half-life for specific M3–chemokine complexes. In
the context of the extracellular milieu, where these components are not likely to be in equilibrium, complex stability
may in fact dictate whether a given chemokine will be effectively targeted by M3.
Chemokines play a critical role in leukocyte recruitment,
and therefore, antagonism of the chemokine system represents a promising antiinflammatory strategy relevant not only
to viruses but also to medical therapeutics. The high degree
of redundancy among individual ligands and receptors has
classically presented an inherent difficulty in targeting the chemokine network. The M3 decoy receptor is an ideal agent in
this regard, because it exhibits the most broad-spectrum inhibition of any known chemokine decoy receptor and is further
capable of blocking both GPCR and GAG interactions. Not
surprisingly, M3 has shown promise as an antiinflammatory
therapeutic in several models, including tumor rejection (48),
vascular injury (49), aortic allograft rejection (50), and CCL21induced lymphocytic infiltration of pancreatic islets (51).
More recent experiments have shown that islet-specific M3
expression can also prevent inflammatory recruitment, islet
destruction, and subsequent diabetes in mouse insulitis models (52). This study describes in precise detail the structural
basis for chemokine inhibition by the M3 viral decoy receptor, revealing the importance of dual mimicry of both GPCRs
and GAGs in the establishment of broad-spectrum antiinflammatory activity.
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XCL1 was injected, and for wild-type M3 binding by competition, XCL1
was preequilibrated with M3 and injected over the M3BBXB chip in the
same manner.
To measure chemokine binding to heparin and M3 competition, heparin
sensor chips were prepared by neutravidin capture of biotinylated heparin.
Neutravidin (Thermo Fisher Scientific) was coupled to a CM5 chip in 10 mM
sodium citrate, pH 4.5, using standard amine chemistry. 15-kD heparinbiotin was injected at 5 mg/ml in Hepes running buffer with 300 mM NaCl
and bound to a level of ⵑ150–300 RU. For heparin binding, chemokines
were injected at 20 l/min CCL2, and 80 l/min XCL1 and CXCL10,
and for M3 competition assays, chemokines were preequilibrated with M3
and injected over the heparin chip in the same manner. The resulting estimates for XCL1 and CXCL10 affinity by this assay are greater than CCL2,
which is unexpected, because CCL2 is predicted to be much higher affinity.
A likely explanation is that the KI for CCL2 is beyond the limits of detection
of the competition assay when conducted in the micromolar range (CCL2),
and therefore, the KI represents a lower limit for the true dissociation constant in this case.
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Competition titration curves were fit to eqs. 1 and 2 (referred to as
eqs. 1 and 6 in Supplemental materials and methods) using the program
Scientist (Micromath) to yield KI (1/KM∗) for M3 binding to chemokines
in competition with the chip-bound receptor. The assay was conducted
in the same manner for the M3BBXB or heparin competition assays, where
M denotes M3BBXB or heparin on the chip and M∗ is M3 (competitor)
in solution.
Flow cytometry. XCL1 and VEGF (PeproTech) were nonspecifically biotinylated with Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific), and CCL2
and CXCL10 were site-specifically biotinylated using BirA ligase (courtesy of
M. Fremont, Washington University, St. Louis, MO) according to standard
protocol (Avidity). Streptavidin-PE was purchased from BD Biosciences.
CHO-K1 and -745 cell lines were a gift from L. Zhang (Washington University, St. Louis, MO) and cultured as previously described (66). To analyze
chemokine binding to GAGs on CHO cells, 5 × 105 cells were stained with
1–2 g of each chemokine in 200 μl PBS with 10% FBS. After washing, the
cells were stained with 1 g streptavidin-PE. Flow cytometry was conducted
on a flow cytometer (FACScan; BD Biosciences). For competition experiments, the cells were incubated with chemokines in the presence of equal
molar amounts of M3.
Coordinates. The coordinates of M3–CCL2 and M3–XCL1 are available from
the Protein Data Bank under accession nos. 2NZ1 and 2NYZ, respectively.
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